Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT ID: NCT06260722
Last Updated: 2025-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1250 participants
INTERVENTIONAL
2024-02-21
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
NCT06559722
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT04287179
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
NCT01885208
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03882970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retatrutide Dose Level 1
Participants will receive retatrutide administered subcutaneously (SC).
Retatrutide
Administered SC.
Retatrutide Dose Level 2
Participants will receive retatrutide administered SC.
Retatrutide
Administered SC.
Semaglutide
Participants will receive semaglutide administered SC.
Semaglutide
Administered SC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Retatrutide
Administered SC.
Semaglutide
Administered SC.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have HbA1c ≥ 7.0% (53 millimoles per mole (mmol/mol)) to ≤ 10.5% (91 mmol/mol)
* Have been on a stable diabetes treatment consisting of metformin ≥ 1500 milligrams per day (mg/day) with or without SGLT2i during 90 days prior to screening
* Are of stable weight for at least 90 days prior to screening
* Have a Body Mass Index (BMI) ≥ 25.0 kilograms per meter squared (kg/m\^2)
Exclusion Criteria
* Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
* Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
* Have an estimated glomerular filtration rate (eGFR) \<45 milliliters/minute/1.73 meter squared (mL/min/1.73 m\^2) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratory
* Have a prior or planned surgical treatment for obesity
* Have New York Heart Association Functional Classification IV congestive heart failure
* Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
* Have a known clinically significant gastric emptying abnormality
* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
* Have any lifetime history of a suicide attempt
* Had chronic or acute pancreatitis
* Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
* Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama - Department of Nutrition Sciences
Birmingham, Alabama, United States
Neighborhood Healthcare Institute of Health
Escondido, California, United States
Long Beach Research Institute
Long Beach, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Arrow Clinical Trials
Daytona Beach, Florida, United States
New Age Medical Research Corporation
Miami, Florida, United States
South Broward Research
Miramar, Florida, United States
Clinical Research of Central Florida
Winter Haven, Florida, United States
Herman Clinical Research
Suwanee, Georgia, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, United States
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Deaconess Clinic - Gateway Health Center
Newburgh, Indiana, United States
IMA Clinical Research Monroe - Armand
Monroe, Louisiana, United States
MedStar Health Research Institute (MedStar Physician Based Research Network)
Hyattsville, Maryland, United States
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, United States
NECCR PrimaCare Research
Fall River, Massachusetts, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, United States
Palm Research Center Tenaya
Las Vegas, Nevada, United States
Palm Research Center Sunset
Las Vegas, Nevada, United States
NYC Research INC
Long Island City, New York, United States
Medication Management
Greensboro, North Carolina, United States
Remington Davis Clinical Research
Columbus, Ohio, United States
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Central States Research
Tulsa, Oklahoma, United States
The Corvallis Clinic, P.C.
Corvallis, Oregon, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Valley Institute of Research - Fort Worth
Fort Worth, Texas, United States
Juno Research
Houston, Texas, United States
Southern Endocrinology Associates
Mesquite, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Texas Valley Clinical Research
Weslaco, Texas, United States
Medrasa Clinical Research
Wylie, Texas, United States
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, United States
IMA Clinical Research West Virginia
Morgantown, West Virginia, United States
CARE - Centro de Alergia y Enfermedades Respiratorias
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Stat Research S.A.
Buenos Aires, Buenos Aires F.D., Argentina
CIPREC
Buenos Aires, Buenos Aires F.D., Argentina
Centro Médico Viamonte
Buenos Aires, Buenos Aires F.D., Argentina
Mautalen Salud e Investigación
Buenos Aires, Buenos Aires F.D., Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Buenos Aires F.D., Argentina
CEMEDIAB
C.a.b.a., Buenos Aires F.D., Argentina
Instituto Centenario
CABA, Buenos Aires F.D., Argentina
Centro Medico Privado San Vicente Diabetes
Córdoba, Córdoba Province, Argentina
CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
Godoy Cruz, Mendoza Province, Argentina
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, Santa Fe Province, Argentina
Instituto de Investigaciones Clinicas Rosario
Rosario, Santa Fe Province, Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, , Argentina
Fundación Respirar
Buenos Aires, , Argentina
Centro Diabetológico Dr. Waitman
Córdoba, , Argentina
University of Calgary - Clinical Trials Unit
Calgary, Alberta, Canada
Alberta Diabetes Institute
Edmonton, Alberta, Canada
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada
Aggarwal and Associates Limited
Brampton, Ontario, Canada
Winterberry Research Inc.
Hamilton, Ontario, Canada
The Wharton Medical Clinic Clinical Trials Inc
Hamilton, Ontario, Canada
Hamilton Medical Research Group
Hamilton, Ontario, Canada
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, Canada
Prime Health Clinical Research
Toronto, Ontario, Canada
Maple Leaf Research
Toronto, Ontario, Canada
Private Practice - Dr. Nigel Jagan
Whitby, Ontario, Canada
9109-0126 Quebec Inc.
Montreal, Quebec, Canada
Diseno y Planeacion en Investigacion Medica
Guadalajara, Jalisco, Mexico
RM Pharma Specialists
Mexico City, Mexico City, Mexico
Hospital de Jésus, I.A.P.
Mexico City, Mexico City, Mexico
Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
Mexico City, Mexico City, Mexico
Instituto de Diabetes, Obesidad y Nutricion
Cuernavaca, Morelos, Mexico
Cardiolink Clin Trials
Monterrey, Nuevo León, Mexico
Clínica García Flores SC
Monterrey, Nuevo León, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico
Enclifar Ensayos Clínicos Farmacológicos Sc
Chihuahua City, , Mexico
Instituto Veracruzano en Investigación Clínica S.C.
Veracruz, , Mexico
Advanced Clinical Research, LLC
Bayamón, , Puerto Rico
GCM Medical Group, PSC - Hato Rey Site
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J1I-MC-GZBZ
Identifier Type: OTHER
Identifier Source: secondary_id
18805
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.